Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362153 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT01362153 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 49 participants.
The verdict
NCT01362153, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.
Interventions
- DRUG Golimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-12-26 |
| Est. Completion | 2009-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01362153
The ClinicalTrials.gov registry entry for NCT01362153 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Golimumab is the first listed.
NCT01362153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01362153 about?
NCT01362153 is a clinical study titled "A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)". This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.
What is the current status of trial NCT01362153?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2007-12-26. Estimated completion is 2009-02-27.
What interventions are being tested in trial NCT01362153?
The interventions under investigation include: Golimumab (DRUG).
Who is sponsoring clinical trial NCT01362153?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.